Selective repopulation of normal mouse liver by Fas/CD95-resistant hepatocytes

Authors:
  • OSOlivier Soubrane
    Olivier Soubrane

Abstract
Hepatocyte transplantation might represent a potential therapeutic alternative to liver transplantation in the future1,2; however, transplanted cells have a limited capacity to repopulate the liver, as they do not proliferate under normal conditions. Recently, studies in urokinase (uPA) transgenic mice3,4,5 and in fumarylacetoacetate hydrolase (FAH)-deficient mice6 have shown that the liver can be repopulated by genetically engineered hepatocytes harboring a selective advantage over resident hepatocytes7. We have reported that transgenic mice expressing human Bcl-2 in their hepatocytes are protected from Fas/CD95-mediated liver apoptosis8. We now show that Bcl-2 transplanted hepatocytes selectively repopulate the liver of mice treated with nonlethal doses of the anti-Fas antibody Jo2. FK 506 immunosuppressed mice were transplanted by splenic injection with Bcl-2 hepatocytes. The livers of female recipients were repopulated by male Bcl-2 transgenic hepatocytes, as much as 16%, after 8 to 12 administrations of Jo2. This only occurred after anti-Fas treatment, confirming that resistance to Fas-induced apoptosis constituted the selective advantage of these transplanted hepatocytes. Thus, we have demonstrated a method for increasing genetic reconstitution of the liver through selective repopulation with modified transgenic hepatocytes, which will allow optimization of cell and gene therapy in the liver.

This publication has 16 references indexed in Scilit: